Kiadis to Host Key Opinion Leader Meeting on Addressing the Risks of Haloidentical HSCT in Blood Cancer

Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations for patients suffering from blood cancers and inherited blood disorders safer and more effective, today announced it will host a Key Opinion Leader meeting on the topic of ‘Addressing the Risks of Haploidentical HSCT in Blood Cancer’ on Wednesday, May 31 from 12:00pm – 1:30pm Eastern Time in New York City.